108 related articles for article (PubMed ID: 22605655)
21. Impact of MMX® mesalamine on improvement and maintenance of health-related quality of life in patients with ulcerative colitis.
Hodgkins P; Yen L; Yarlas A; Karlstadt R; Solomon D; Kane S
Inflamm Bowel Dis; 2013 Feb; 19(2):386-96. PubMed ID: 22648999
[TBL] [Abstract][Full Text] [Related]
22. miR-206 as a Biomarker for Response to Mesalamine Treatment in Ulcerative Colitis.
Minacapelli CD; Bajpai M; Geng X; Van Gurp J; Poplin E; Amenta PS; Brant SR; Das KM
Inflamm Bowel Dis; 2019 Jan; 25(1):78-84. PubMed ID: 30204869
[TBL] [Abstract][Full Text] [Related]
23. eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis.
Pedersen N; Thielsen P; Martinsen L; Bennedsen M; Haaber A; Langholz E; Végh Z; Duricova D; Jess T; Bell S; Burisch J; Munkholm P
Inflamm Bowel Dis; 2014 Dec; 20(12):2276-85. PubMed ID: 25248002
[TBL] [Abstract][Full Text] [Related]
24. Severe eosinophilic infiltration in colonic biopsies predicts patients with ulcerative colitis not responding to medical therapy.
Zezos P; Patsiaoura K; Nakos A; Mpoumponaris A; Vassiliadis T; Giouleme O; Pitiakoudis M; Kouklakis G; Evgenidis N
Colorectal Dis; 2014 Dec; 16(12):O420-30. PubMed ID: 25040651
[TBL] [Abstract][Full Text] [Related]
25. Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations.
Planell N; Lozano JJ; Mora-Buch R; Masamunt MC; Jimeno M; Ordás I; Esteller M; Ricart E; Piqué JM; Panés J; Salas A
Gut; 2013 Jul; 62(7):967-76. PubMed ID: 23135761
[TBL] [Abstract][Full Text] [Related]
26. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
Flourié B; Hagège H; Tucat G; Maetz D; Hébuterne X; Kuyvenhoven JP; Tan TG; Pierik MJ; Masclee AA; Dewit O; Probert CS; Aoucheta D;
Aliment Pharmacol Ther; 2013 Apr; 37(8):767-75. PubMed ID: 23451806
[TBL] [Abstract][Full Text] [Related]
27. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
[TBL] [Abstract][Full Text] [Related]
28. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis.
Mak WY; Buisson A; Andersen MJ; Lei D; Pekow J; Cohen RD; Kahn SA; Pereira B; Rubin DT
Dig Dis Sci; 2018 May; 63(5):1294-1301. PubMed ID: 29468374
[TBL] [Abstract][Full Text] [Related]
29. Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study.
Hyams JS; Davis Thomas S; Gotman N; Haberman Y; Karns R; Schirmer M; Mo A; Mack DR; Boyle B; Griffiths AM; LeLeiko NS; Sauer CG; Keljo DJ; Markowitz J; Baker SS; Rosh J; Baldassano RN; Patel A; Pfefferkorn M; Otley A; Heyman M; Noe J; Oliva-Hemker M; Rufo PA; Strople J; Ziring D; Guthery SL; Sudel B; Benkov K; Wali P; Moulton D; Evans J; Kappelman MD; Marquis MA; Sylvester FA; Collins MH; Venkateswaran S; Dubinsky M; Tangpricha V; Spada KL; Saul B; Wang J; Serrano J; Hommel K; Marigorta UM; Gibson G; Xavier RJ; Kugathasan S; Walters T; Denson LA
Lancet; 2019 Apr; 393(10182):1708-1720. PubMed ID: 30935734
[TBL] [Abstract][Full Text] [Related]
30. Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis.
Leifeld L; Pfützer R; Morgenstern J; Gibson PR; Marakhouski Y; Greinwald R; Mueller R; Kruis W
Aliment Pharmacol Ther; 2011 Nov; 34(9):1115-22. PubMed ID: 21923715
[TBL] [Abstract][Full Text] [Related]
31. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.
D'Haens G; Sandborn WJ; Barrett K; Hodgson I; Streck P
Am J Gastroenterol; 2012 Jul; 107(7):1064-77. PubMed ID: 22565161
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis.
Chojnacki C; Wisniewska-Jarosinska M; Walecka-Kapica E; Klupinska G; Jaworek J; Chojnacki J
J Physiol Pharmacol; 2011 Jun; 62(3):327-34. PubMed ID: 21893693
[TBL] [Abstract][Full Text] [Related]
33. Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naïve ulcerative colitis during active and quiescent disease.
Matsuda R; Koide T; Tokoro C; Yamamoto T; Godai T; Morohashi T; Fujita Y; Takahashi D; Kawana I; Suzuki S; Umemura S
Inflamm Bowel Dis; 2009 Mar; 15(3):328-34. PubMed ID: 18942752
[TBL] [Abstract][Full Text] [Related]
34. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy.
De Vos M; Louis EJ; Jahnsen J; Vandervoort JG; Noman M; Dewit O; Dʼhaens GR; Franchimont D; Baert FJ; Torp RA; Henriksen M; Potvin PM; Van Hootegem PP; Hindryckx PM; Moreels TG; Collard A; Karlsen LN; Kittang E; Lambrecht G; Grimstad T; Koch J; Lygren I; Coche JC; Mana F; Van Gossum A; Belaiche J; Cool MR; Fontaine F; Maisin JM; Muls V; Neuville B; Staessen DA; Van Assche GA; de Lange T; Solberg IC; Vander Cruyssen BJ; Vermeire SA
Inflamm Bowel Dis; 2013 Sep; 19(10):2111-7. PubMed ID: 23883959
[TBL] [Abstract][Full Text] [Related]
35. Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study.
Watanabe M; Hanai H; Nishino H; Yokoyama T; Terada T; Suzuki Y
Inflamm Bowel Dis; 2013 Jul; 19(8):1681-90. PubMed ID: 23624890
[TBL] [Abstract][Full Text] [Related]
36. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
[TBL] [Abstract][Full Text] [Related]
37. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis.
Sinha A; Nightingale J; West KP; Berlanga-Acosta J; Playford RJ
N Engl J Med; 2003 Jul; 349(4):350-7. PubMed ID: 12878742
[TBL] [Abstract][Full Text] [Related]
38. Effects of AVX-470, an Oral, Locally Acting Anti-Tumour Necrosis Factor Antibody, on Tissue Biomarkers in Patients with Active Ulcerative Colitis.
Hartman DS; Tracey DE; Lemos BR; Erlich EC; Burton RE; Keane DM; Patel R; Kim S; Bhol KC; Harris MS; Fox BS
J Crohns Colitis; 2016 Jun; 10(6):641-9. PubMed ID: 26802087
[TBL] [Abstract][Full Text] [Related]
39. Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis - a randomized, placebo-controlled, pilot study.
Singla V; Pratap Mouli V; Garg SK; Rai T; Choudhury BN; Verma P; Deb R; Tiwari V; Rohatgi S; Dhingra R; Kedia S; Sharma PK; Makharia G; Ahuja V
J Crohns Colitis; 2014 Mar; 8(3):208-14. PubMed ID: 24011514
[TBL] [Abstract][Full Text] [Related]
40. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.
Frieri G; Giacomelli R; Pimpo M; Palumbo G; Passacantando A; Pantaleoni G; Caprilli R
Gut; 2000 Sep; 47(3):410-4. PubMed ID: 10940280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
